{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:38:26Z","timestamp":1783726706055,"version":"3.55.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1013752","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000}}],"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"National Institute of Health","award":["P51 OD011132"],"award-info":[{"award-number":["P51 OD011132"]}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201400004C; 75N93021C00017; R01AI188896"],"award-info":[{"award-number":["HHSN272201400004C; 75N93021C00017; R01AI188896"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007623","name":"School of Medicine, Emory University","doi-asserted-by":"publisher","award":["Emory Executive Vice President for Health Affairs Synergy Fund Award"],"award-info":[{"award-number":["Emory Executive Vice President for Health Affairs Synergy Fund Award"]}],"id":[{"id":"10.13039\/100007623","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children's Helathcare of Atlanta","award":["Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children\u2019s Healthcare of Atlanta"],"award-info":[{"award-number":["Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children\u2019s Healthcare of Atlanta"]}]},{"DOI":"10.13039\/100007623","name":"School of Medicine, Emory University","doi-asserted-by":"publisher","award":["I3 Synergy Awards, COVID-19 Cures"],"award-info":[{"award-number":["I3 Synergy Awards, COVID-19 Cures"]}],"id":[{"id":"10.13039\/100007623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031214","name":"Woodruff Health Sciences Center","doi-asserted-by":"crossref","award":["2020 COVID-19 CURE Award"],"award-info":[{"award-number":["2020 COVID-19 CURE Award"]}],"id":[{"id":"10.13039\/100031214","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutions of Health","doi-asserted-by":"crossref","award":["Division of Intramural Research"],"award-info":[{"award-number":["Division of Intramural Research"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>COVID-19 vaccines provide robust protection against severe disease, hospitalization, and death. Neutralizing antibodies are a strong correlate of protection and can prevent SARS-CoV-2 infection of the lungs. We used a conventional laboratory mouse model combined with high- or low-dose vaccination to understand the early immunological response following SARS-CoV-2 infection in the lungs of vaccinated mice. The lungs of high-dose vaccinated mice were completely protected against SARS-CoV-2 infection whereas low-dose vaccinated mice were partially protected. We observed a greater influx of total monocytes, macrophages, dendritic cells, neutrophils, and eosinophils in the lungs of low-dose vaccinated mice compared to na\u00efve infected mice. The different proportions of innate immune cells in the lungs indicated that infection in low-dose vaccinated mice induces a unique inflammatory environment compared to na\u00efve infected or uninfected mice. A prominent feature of infection of low-dose vaccinated mice was infiltration of eosinophils in the lungs, which we observed across different COVID-19 vaccines and SARS-CoV-2 variants. Single cell transcriptional profiling of lung parenchymal immune cells showed that viral RNA was predominantly associated with eosinophils. Eosinophils from low-dose vaccinated mice were transcriptionally distinct from na\u00efve mice after challenge and showed an IFN-\u03b3 biased signature. Further, monocytes from low-dose vaccinated mice expressed eotaxin-2, suggesting a monocyte-eosinophil signaling axis. Antibody mediated depletion of eosinophils in low-dose vaccinated mice resulted in increased virus replication and dissemination in the lungs. These findings demonstrate the protective nature of eosinophils during SARS-CoV-2 infection in the context of vaccination and highlight quantitative and qualitative differences in the immune response in a model for vaccine breakthrough infection.<\/jats:p>","DOI":"10.1371\/journal.ppat.1013752","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:51:01Z","timestamp":1764701461000},"page":"e1013752","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Monocyte-eosinophil signaling axis promotes vaccine-mediated protection against SARS-CoV-2"],"prefix":"10.1371","volume":"21","author":[{"given":"Kathryn M.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Elrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elliott","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Vander","family":"Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansa","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Lapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Bosinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet D.","family":"Menachery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Rao","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"Kohlmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Grakoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-8380","authenticated-orcid":true,"given":"Mehul S.","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"7","key":"ppat.1013752.ref001","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"6561","key":"ppat.1013752.ref002","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"KS Corbett","year":"2021","journal-title":"Science"},{"key":"ppat.1013752.ref003","first-page":"80","article-title":"Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination","volume-title":"N Engl J Med","author":"AT Widge","year":"2021"},{"issue":"6561","key":"ppat.1013752.ref004","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"A Pegu","year":"2021","journal-title":"Science"},{"issue":"10328","key":"ppat.1013752.ref005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"DR Feikin","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"ppat.1013752.ref006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"LR Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"ppat.1013752.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.03.038","article-title":"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron","volume":"185","author":"M Gagne","year":"2022","journal-title":"Cell"},{"issue":"2","key":"ppat.1013752.ref008","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1056\/NEJMc2214293","article-title":"Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster","volume":"388","author":"ME Davis-Gardner","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"ppat.1013752.ref009","doi-asserted-by":"crossref","first-page":"100529","DOI":"10.1016\/j.xcrm.2022.100529","article-title":"mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant","volume":"3","author":"V-V Edara","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"ppat.1013752.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant","volume":"29","author":"VV Edara","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"7","key":"ppat.1013752.ref011","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMc2107799","article-title":"Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants","volume":"385","author":"V-V Edara","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"ppat.1013752.ref012","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine","volume":"12","author":"B Mizrahi","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"ppat.1013752.ref013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"M Lipsitch","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"ppat.1013752.ref014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"MS Diamond","year":"2022","journal-title":"Nat Immunol"},{"issue":"6","key":"ppat.1013752.ref015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"M Liao","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"ppat.1013752.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.03.005","article-title":"Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19","volume":"54","author":"PA Szabo","year":"2021","journal-title":"Immunity"},{"issue":"12","key":"ppat.1013752.ref017","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201012","article-title":"Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19","volume":"217","author":"C Radermecker","year":"2020","journal-title":"J Exp Med"},{"issue":"12","key":"ppat.1013752.ref018","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201241","article-title":"Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling","volume":"217","author":"B Israelow","year":"2020","journal-title":"J Exp Med"},{"issue":"6","key":"ppat.1013752.ref019","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02749-21","article-title":"CCR2 Signaling Restricts SARS-CoV-2 Infection","volume":"12","author":"A Vanderheiden","year":"2021","journal-title":"mBio"},{"key":"ppat.1013752.ref020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74623","article-title":"ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFN\u03b3-driven immunopathology","volume":"11","author":"R Gawish","year":"2022","journal-title":"Elife"},{"issue":"3","key":"ppat.1013752.ref021","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4269\/ajtmh.20-0762","article-title":"Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection","volume":"103","author":"GB Moreau","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"6511","key":"ppat.1013752.ref022","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"H Gu","year":"2020","journal-title":"Science"},{"issue":"12","key":"ppat.1013752.ref023","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201129","article-title":"SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology","volume":"217","author":"FP Veras","year":"2020","journal-title":"J Exp Med"},{"issue":"15","key":"ppat.1013752.ref024","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"C Qin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ppat.1013752.ref025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.174133","article-title":"Neutrophil proteases are protective against SARS-CoV-2 by degrading the spike protein and dampening virus-mediated inflammation","volume":"9","author":"NG Leborgne","year":"2024","journal-title":"JCI Insight"},{"issue":"18","key":"ppat.1013752.ref026","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1001\/jama.2021.4388","article-title":"Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination","volume":"325","author":"VV Edara","year":"2021","journal-title":"JAMA"},{"key":"ppat.1013752.ref027","doi-asserted-by":"crossref","first-page":"766112","DOI":"10.3389\/fimmu.2021.766112","article-title":"Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19","volume":"12","author":"TNM Tran","year":"2021","journal-title":"Front Immunol"},{"key":"ppat.1013752.ref028","first-page":"100474","article-title":"Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial","volume":"24","author":"TP Nguyen","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"ppat.1013752.ref029","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41541-022-00589-4","article-title":"Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial","volume":"7","author":"LT-C Liu","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"1","key":"ppat.1013752.ref030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nprot.2014.005","article-title":"Intravascular staining for discrimination of vascular and tissue leukocytes","volume":"9","author":"KG Anderson","year":"2014","journal-title":"Nat Protoc"},{"issue":"10","key":"ppat.1013752.ref031","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00014-18","article-title":"Dynamics of Tissue-Specific CD8+ T Cell Responses during West Nile Virus Infection","volume":"92","author":"R Aguilar-Valenzuela","year":"2018","journal-title":"J Virol"},{"issue":"578","key":"ppat.1013752.ref032","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe8146","article-title":"Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys","volume":"13","author":"E Speranza","year":"2021","journal-title":"Sci Transl Med"},{"issue":"3","key":"ppat.1013752.ref033","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.02.001","article-title":"A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs","volume":"54","author":"NK Routhu","year":"2021","journal-title":"Immunity"},{"issue":"11","key":"ppat.1013752.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001284","article-title":"Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge","volume":"19","author":"A Muruato","year":"2021","journal-title":"PLoS Biol"},{"issue":"1","key":"ppat.1013752.ref035","doi-asserted-by":"crossref","first-page":"112038","DOI":"10.1016\/j.celrep.2023.112038","article-title":"Ablation of Adar1 in myeloid cells imprints a global antiviral state in the lung and heightens early immunity against SARS-CoV-2","volume":"42","author":"JZ Adamska","year":"2023","journal-title":"Cell Rep"},{"issue":"43","key":"ppat.1013752.ref036","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ppat.1013752.ref037","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.4049\/jimmunol.165.10.5839","article-title":"Murine eotaxin-2: a constitutive eosinophil chemokine induced by allergen challenge and IL-4 overexpression","volume":"165","author":"N Zimmermann","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"ppat.1013752.ref038","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"ppat.1013752.ref039","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/JLB.1MR1117-442RR","article-title":"Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease","volume":"104","author":"H Abdala-Valencia","year":"2018","journal-title":"J Leukoc Biol"},{"issue":"9","key":"ppat.1013752.ref040","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"C Mesnil","year":"2016","journal-title":"J Clin Invest"},{"key":"ppat.1013752.ref041","doi-asserted-by":"crossref","first-page":"802839","DOI":"10.3389\/fimmu.2021.802839","article-title":"Transcriptional Profiling of Mouse Eosinophils Identifies Distinct Gene Signatures Following Cellular Activation","volume":"12","author":"A Dolitzky","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"ppat.1013752.ref042","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.immuni.2016.03.003","article-title":"Cystatin F Ensures Eosinophil Survival by Regulating Granule Biogenesis","volume":"44","author":"SP Matthews","year":"2016","journal-title":"Immunity"},{"issue":"10","key":"ppat.1013752.ref043","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"DM Del Valle","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"ppat.1013752.ref044","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"ES Winkler","year":"2021","journal-title":"Cell"},{"issue":"1","key":"ppat.1013752.ref045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"HF Rosenberg","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"ppat.1013752.ref046","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2007-01-071340","article-title":"Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus","volume":"110","author":"S Phipps","year":"2007","journal-title":"Blood"},{"issue":"8","key":"ppat.1013752.ref047","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.4049\/jimmunol.1600787","article-title":"Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus","volume":"198","author":"AE Samarasinghe","year":"2017","journal-title":"J Immunol"},{"issue":"1","key":"ppat.1013752.ref048","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/JLB.4MA0320-343R","article-title":"Influenza A virus directly modulates mouse eosinophil responses","volume":"108","author":"KS LeMessurier","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"10","key":"ppat.1013752.ref049","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1084\/jem.190.10.1465","article-title":"Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects","volume":"190","author":"DJ Adamko","year":"1999","journal-title":"J Exp Med"},{"issue":"3","key":"ppat.1013752.ref050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1165\/rcmb.2015-0405OC","article-title":"Human and Mouse Eosinophils Have Antiviral Activity against Parainfluenza Virus","volume":"55","author":"MG Drake","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"ppat.1013752.ref051","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1086\/515322","article-title":"Recombinant human eosinophil-derived neurotoxin\/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus","volume":"177","author":"JB Domachowske","year":"1998","journal-title":"J Infect Dis"},{"issue":"14","key":"ppat.1013752.ref052","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1093\/nar\/26.14.3358","article-title":"Eosinophil cationic protein\/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity","volume":"26","author":"JB Domachowske","year":"1998","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"ppat.1013752.ref053","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.4049\/jimmunol.162.5.2997","article-title":"IL-5 and eosinophils are essential for the development of airway hyperresponsiveness following acute respiratory syncytial virus infection","volume":"162","author":"J Schwarze","year":"1999","journal-title":"J Immunol"},{"issue":"3","key":"ppat.1013752.ref054","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/JVI.01536-14","article-title":"Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease","volume":"89","author":"Y-C Su","year":"2015","journal-title":"J Virol"},{"issue":"1","key":"ppat.1013752.ref055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.04.005","article-title":"Respiratory viruses and eosinophils: exploring the connections","volume":"83","author":"HF Rosenberg","year":"2009","journal-title":"Antiviral Res"},{"issue":"1","key":"ppat.1013752.ref056","article-title":"Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters","volume":"20","author":"JG-B Diego","year":"2024","journal-title":"PLoS Pathog"},{"key":"ppat.1013752.ref057","doi-asserted-by":"crossref","first-page":"1217181","DOI":"10.3389\/fimmu.2023.1217181","article-title":"Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia","volume":"14","author":"LA Chang","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"ppat.1013752.ref058","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.06.018","article-title":"COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge","volume":"54","author":"AT DiPiazza","year":"2021","journal-title":"Immunity"},{"issue":"23","key":"ppat.1013752.ref059","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"M Bolles","year":"2011","journal-title":"J Virol"},{"issue":"1","key":"ppat.1013752.ref060","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4049\/jimmunol.0802270","article-title":"Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice","volume":"183","author":"CM Percopo","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"ppat.1013752.ref061","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","author":"J Chin","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"ppat.1013752.ref062","first-page":"435","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"VA Fulginiti","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"ppat.1013752.ref063","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"HW Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"10","key":"ppat.1013752.ref064","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.4049\/jimmunol.181.10.6692","article-title":"Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease","volume":"181","author":"EM Castilow","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"ppat.1013752.ref065","doi-asserted-by":"crossref","first-page":"27133","DOI":"10.1038\/s41598-024-78602-0","article-title":"Eosinophils mitigate intestinal fibrosis while promoting inflammation in a chronic DSS colitis model and co-culture model with fibroblasts","volume":"14","author":"I Jacobs","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"ppat.1013752.ref066","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI118456","article-title":"Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils","volume":"97","author":"PD Ponath","year":"1996","journal-title":"J Clin Invest"},{"issue":"5","key":"ppat.1013752.ref067","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI119624","article-title":"High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines","volume":"100","author":"M Uguccioni","year":"1997","journal-title":"J Clin Invest"},{"issue":"86","key":"ppat.1013752.ref068","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf8161","article-title":"Exposure to lung-migrating helminth protects against murine SARS-CoV-2 infection through macrophage-dependent T cell activation","volume":"8","author":"OO Oyesola","year":"2023","journal-title":"Sci Immunol"},{"issue":"7","key":"ppat.1013752.ref069","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14047","article-title":"Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia","volume":"75","author":"M Cazzaniga","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"2","key":"ppat.1013752.ref070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/all.14455","article-title":"Eosinopenia is associated with greater severity in patients with coronavirus disease 2019","volume":"76","author":"L Zhao","year":"2021","journal-title":"Allergy"},{"key":"ppat.1013752.ref071","first-page":"9621572","article-title":"Asthma and COVID-19: Emphasis on Adequate Asthma Control","volume":"2021","author":"DD Nassoro","year":"2021","journal-title":"Can Respir J"},{"issue":"3","key":"ppat.1013752.ref072","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/aam.aam_41_21","article-title":"A study to evaluate the role of eosinophil count as a prognostic marker for assessing the outcome in patients with COVID-19 infection","volume":"21","author":"V Krishnamurthy","year":"2022","journal-title":"Ann Afr Med"},{"issue":"1","key":"ppat.1013752.ref073","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anai.2021.02.021","article-title":"The relationship between asthma, eosinophilia, and outcomes in coronavirus disease 2019 infection","volume":"127","author":"KS Ho","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"ppat.1013752.ref074","article-title":"The Association of Asthma With COVID-19 Mortality: An Updated Meta-Analysis Based on Adjusted Effect Estimates","volume":"9","author":"H Hou","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"ppat.1013752.ref075","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.01.011","article-title":"Association between allergic conditions and COVID-19 susceptibility and outcomes","volume":"132","author":"C Chen","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"15","key":"ppat.1013752.ref076","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"J Bousquet","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"ppat.1013752.ref077","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.anai.2021.03.017","article-title":"Eosinophils in antiviral immunity and (perhaps) a benefit of having asthma during the SARS-CoV2 pandemic","volume":"127","author":"R Eid","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"ppat.1013752.ref078","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"RE Chen","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"ppat.1013752.ref079","doi-asserted-by":"crossref","DOI":"10.1002\/cpim.116","article-title":"Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies","volume":"131","author":"A Vanderheiden","year":"2020","journal-title":"Curr Protoc Immunol"},{"issue":"19","key":"ppat.1013752.ref080","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00985-20","article-title":"Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures","volume":"94","author":"A Vanderheiden","year":"2020","journal-title":"J Virol"},{"issue":"11","key":"ppat.1013752.ref081","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41592-023-02014-7","article-title":"Extending support for mouse data in the Molecular Signatures Database (MSigDB)","volume":"20","author":"AS Castanza","year":"2023","journal-title":"Nat Methods"},{"issue":"10","key":"ppat.1013752.ref082","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006862","article-title":"Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus","volume":"12","author":"LC Katzelnick","year":"2018","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1013752","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T18:39:44Z","timestamp":1765305584000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013752"}},"subtitle":[],"editor":[{"given":"Xiu-Feng","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":82,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1013752","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}